Cargando…
The Combination of Predictive Factors of Pharmacokinetic Origin Associates with Enhanced Disease Control during Treatment of Pediatric Crohn’s Disease with Infliximab
Infliximab (IFX) concentrations are a predictive factor (PF) of pharmacokinetic (PK) origin in the treatment of Crohn’s disease (CD). We evaluated Clearance, another PF of PK origin, either alone or in combination with concentrations. They were evaluated from two cohorts, the first designed to recei...
Autores principales: | Dubinsky, Marla C., Rabizadeh, Shervin, Panetta, John C., Spencer, Elizabeth A., Everts-van der Wind, Annelie, Dervieux, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10610097/ https://www.ncbi.nlm.nih.gov/pubmed/37896168 http://dx.doi.org/10.3390/pharmaceutics15102408 |
Ejemplares similares
-
Model Informed Precision Dosing Tool Forecasts Trough Infliximab and Associates with Disease Status and Tumor Necrosis Factor-Alpha Levels of Inflammatory Bowel Diseases
por: Primas, Christian, et al.
Publicado: (2022) -
Selective IgA(2) deficiency in a patient with small intestinal Crohn’s disease
por: Canales-Herrerias, Pablo, et al.
Publicado: (2023) -
Profile of infliximab in the treatment of pediatric Crohn’s disease
por: Kierkus, Jaroslaw, et al.
Publicado: (2015) -
Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohn’s Disease
por: Siegel, Corey A, et al.
Publicado: (2021) -
The Association Between Genetic Variants, Pharmacokinetics, and Infliximab Efficacy in Pediatric Patients With Crohn's Disease in China
por: Hu, Wenhui, et al.
Publicado: (2021)